SecBot SecBot

MNKD drug pipeline

MANNKIND CORP · 2 rated drugs
$3.96
−4.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±3.9%
1-day, median of 8 events
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 2 (enrolling)
Time to marketAt least 3-5 years away, assuming successful Phase 2 and Phase 3 trials and subsequent regulatory filings

nintedanib DPI nintedanib Updated Aug 24

What to watch

Watch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.

Bull case
  • Phase 1b INFLO-1 data showed a clean safety profile with zero serious adverse events, zero drug-related GI side effects, zero bronchospasm, zero discontinuations, and only mild/transient cough, directly addressing oral nintedanib's biggest weakness (GI intolerance which causes ~20-30% discontinuation rates).
  • The Technosphere DPI platform is already validated through two FDA-approved products (Afrezza insulin, Furoscix), reducing formulation/device risk vs. a novel platform.
  • The global IPF market is large and growing (oral nintedanib/Ofev is a ~$3B+ franchise for Boehringer Ingelheim) and an inhaled version that improves tolerability could capture significant share or expand the treated population.
Bear case
  • Phase 2 INFLO-2 efficacy data (FVC decline rate) has not yet been tested, positive safety does not guarantee efficacy. Inhaled nintedanib must demonstrate it reaches therapeutic concentrations in lung tissue.
  • Avalyn Pharma (AVLN, IPO April 2026) is developing inhaled nintedanib (AP02) and inhaled pirfenidone (AP01) for the same IPF indication, with a ~$300M IPO war chest to fund Phase 2b/3 trials, direct competition.
  • Oral nintedanib (Ofev by Boehringer Ingelheim) is deeply entrenched as standard-of-care for IPF; physician inertia and payer dynamics may slow inhaled adoption even if approved.
● neutral
Impact
PhasePreclinical / Early-stage development (DPI formulation); Oral formulation is Phase 3 completed / NDA under FDA review
Time to marketThe DPI formulation is early-stage with no clinical trials announced, so potential approval is likely several years away (5+ years under typical timelines). The oral formulation has a PDUFA decision date of June 24, 2027.

ralinepag DPI ralinepag Updated Nov 7

What to watch

The next catalyst for ralinepag overall is the FDA PDUFA decision on the oral formulation on June 24, 2027, but that is a United Therapeutics (UTHR) event. For MannKind's ralinepag DPI program specifically, there is no announced clinical trial start or data readout date. Watch for MannKind to initiate clinical trials for MNKD-1501, which would signal progression of the DPI program. MannKind's nearer-term catalysts include its Q4 2026 profitability target and the SCP-111 FDA decision by December 31, 2026.

Bull case
  • MannKind's proprietary DPI technology is already validated through Tyvaso DPI (marketed by United Therapeutics for PAH) and Afrezza, reducing formulation risk for ralinepag DPI
  • The oral ralinepag Phase 3 data showed a strong 55% risk reduction in clinical worsening, supporting the drug's therapeutic potential; an inhaled version could offer better lung targeting and tolerability
  • MannKind anticipates $1 billion in cumulative revenue from its United Therapeutics collaboration (including Tyvaso DPI and ralinepag DPI) from 2027-2030, suggesting meaningful long-term upside if ralinepag DPI succeeds
Bear case
  • The ralinepag DPI program is early-stage (preclinical/no clinical trials initiated), with no guarantee of successful clinical development or FDA approval
  • United Therapeutics already markets Tyvaso (inhaled treprostinil) for PAH, which could compete with or cannibalize ralinepag DPI if approved
  • MannKind's DPI technology has faced commercial challenges (Afrezza has struggled to gain significant market share despite years on the market)

Other drugs in filings and trials

no drug report yet
  • SCP-111 Last: Approval · Sep 30, 2026
  • Furoscix ReadyFlow Autoinjector Last: PDUFA decision · Jul 26, 2026
  • FUROSCIX ReadyFlow Last: Approval · Jul 23, 2026
  • Afrezza Last: Approval · May 29, 2026
  • FUROSCIX Last: NDA filed · Oct 7, 2025
  • Inhaled Technosphere Insulin 1 trial

Past FDA events & how the stock moved

8 events
DateDrugEvent1 day5 days
Sep 30, 2026SCP-111Approval+18.3%+3.3%
Jul 26, 2026Furoscix ReadyFlow AutoinjectorPDUFA decision−4.4%−5.3%
Jul 23, 2026FUROSCIX ReadyFlowApproval+7.5%+7.0%
May 29, 2026AfrezzaApproval−3.0%−6.6%
May 29, 2026AfrezzaPDUFA decision−3.0%−6.6%
Oct 7, 2025FUROSCIXNDA filed−3.9%−9.9%
Oct 7, 2025FUROSCIXBLA filed−3.9%−9.9%
Jun 27, 2014AFREZZAApproval+3.6%−6.3%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Inhaled Technosphere InsulinInhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational DiabetesPhase 3Completed30Sep 5, 2026